On the Blood Sugar Diet website, Dr Mosley provides a link to evidence indicating that, the more rapid and greater your initial weight loss, the more likely you are to sustain long-term weight loss; and other studies have shown this too (for example,
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7039735/ ).
Just on that study, maybe I'm missing the point, but what it seems to say is that being an early responder was a good predictor of being a long-term responder.
So that could generate a hypothesis for the waterfall chart I showed for a typical lifestyle intervention at the 3-year mark: the left-hand side responders at 3 years perhaps tended to be also responders at much earlier stages.
I'm not sure that there's anything to be gleaned from this about whether one intervention is better than another.
Just so no one is confused: (even) the new weight-loss drugs need to be taken *on top of* changes in diet and exercise, not instead of.
I've seen this nice articulation: these meds allow lifestyle interventions to actually work well, whereas without them, they don't work very well at all, on average. So they allow (many) more people to shift to the left versus that typical waterfall chart I showed.
And as a result, they will allow many more T2D's to achieve remission/reversal. (Although I guess if you have to keep taking them you wouldn't fit the current definition for "remission" - dunno, don't really care.)
Tirpezatide/Mounjaro currently has FDA approval for T2D and is fast-tracked for possible obesity approval. I think people would be very surprised if ti didn't get it, and in the meantime it is being prescribed off-label for weight loss, to the extent that supply constraints allow.
Eric Topol has a useful overview piece from a few weeks ago:
https://erictopol.substack.com/p/the-new-obesity-breakthrough-drugs
Just for weight loss, the results are huge:

With tirzepatide, in the most recent trial, average of 20%+ weight loss at 72 weeks at 10mg-15mg dose.
And Stephen Guyenet had an in-depth look at the development of these drugs last year:
https://forum.diabetes.org.uk/boards/threads/guyenet-on-weight-loss-meds.95831/
The main issues at the moment are cost-effectiveness (borderline at best, at current prices, according to standard health economics analyses); supply issues; injections rather than pills; some gastro etc side-effects during ramp up.
Also, possible need to keep taking them forever, but that's basically the same for any chronic condition.